10-Q quarterly report · filed Oct 27, 2026

Wave Life Sciences Ltd. (WVE) Q3 2026 10-Q Quarterly Report

Short answer

Wave Life Sciences Ltd. (WVE) filed its Q3 2026 10-Q quarterly report on Oct 27, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M with net income of −$62M.

Q3 2026 key financials · XBRL

Revenue
$13M
+479.1% QoQ
Net income
−$62M
−15.0% YoY · +10.7% QoQ
Operating margin
-502.0%
EPS (diluted)
−$0.31
+3.1% YoY · +8.8% QoQ

Source: XBRL data from the Wave Life Sciences Ltd. (WVE) Q3 2026 10-Q on SEC EDGAR. USD.

Wave Life Sciences Ltd. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $13.2M, up $5.6M YoY from $7.6M, entirely from the GSK Collaboration Agreement
  • Net loss $61.9M vs $53.9M YoY, operating loss $66.0M vs $56.4M
  • Highest program spending: other R&D $40.5M, up $5.7M; INHBE $6.4M, up $1.8M
  • Cash and equivalents $197.3M, marketable securities $233.4M; operating cash use $173.3M through nine months
  • Outlook: liquidity expected to fund operations at least twelve months; additional financing may be needed, with clinical data expected in fourth quarter 2026

Risk Factors

  • No material changes to risk factors identified in the 2026 Form 10-Q
  • Carried-forward risks remain those disclosed in Wave Life Sciences’ 2025 Form 10-K

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Wave Life Sciences Ltd. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.